Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates

• Published in: Vaccines (Basel) Vol. 11; no. 11; p. 1682
• Main Authors: Awasthi, Mayanka, Macaluso, Anthony, Myscofski, Dawn, Prigge, Jon, Koide, Fusataka, Noyce, Ryan S., Fogarty, Siobhan, Stillwell, Helen, Goebel, Scott J., Daugherty, Bruce, Nasar, Farooq, Bavari, Sina, Lederman, Seth
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.11.2023
• Subjects: Antibodies; Catheters; COVID-19; Cytokines; Dosage and administration; Effectiveness; Enzymes; horsepox virus; Immunogenetics; Immunogenicity; Immunoglobulin G; Infections; Laboratory animals; Lymphocytes T; Monkeys & apes; Primates; Proteins; Respiratory tract; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Smallpox vaccine; spike protein; Testing; TNX-1800; vaccine; vaccine platform; Vaccines; Viruses; γ-Interferon; United States; United States > US

TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-W...